FDA panel date for Actelion's Tracleer

Actelion (SWX:ATLN) said that on Aug. 9 the FDA's Cardiovascular and Renal Drugs Advisory Committee will review the NDA for its Tracleer bosentan oral endothelin receptor antagonist to treat pulmonary...